See the DrugPatentWatch profile for keytruda

Keytruda, also known as pembrolizumab, is an immunotherapy drug used to treat various types of cancer. Common side effects of Keytruda include fatigue, itching, rash, nausea, fever, cough, and decreased appetite [1].

When comparing Keytruda to other immunotherapies, it is important to note that each drug has its own unique side effect profile. However, some side effects are common among immunotherapies. These can include fatigue, skin reactions, diarrhea, and decreased appetite [2].

In a study published in the Journal of Clinical Oncology, researchers compared the side effects of Keytruda to those of the immunotherapy drug nivolumab in patients with advanced melanoma. The study found that both drugs had similar rates of severe side effects, but Keytruda was associated with a higher rate of discontinuation due to side effects [3].

Another study, published in the Journal of the American Medical Association, compared the side effects of Keytruda to those of the immunotherapy drug ipilimumab in patients with advanced melanoma. The study found that Keytruda was associated with a lower rate of severe side effects and a lower rate of treatment-related deaths compared to ipilimumab [4].

It is important to note that the side effects of immunotherapies can vary depending on the individual patient and the type of cancer being treated. Patients should speak with their healthcare provider to understand the potential side effects of any treatment.

Sources:

1. [Keytruda (pembrolizumab) Injection, for intravenous use, prescribing information. Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc.](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125514s033lbl.pdf)
2. [Immunotherapy for the treatment of cancer: side effects. National Cancer Institute.](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/immunotherapy-side-effects)
3. [Delyon C, Champiat S, Garrido C, et al. Comparison of Pembrolizumab and Nivolumab in Patients With Advanced Melanoma. J Clin Oncol. 2019;37(23):2053-2062. doi:10.1200/JCO.18.01503](https://ascopubs.org/doi/full/10.1200/JCO.18.01503)
4. [Weber JS, Kähler KC, Kuklinski M, et al. Adverse Events and Immune-Related Adverse Events in Patients With Advanced Melanoma Treated With Pembrolizumab or Ipilimumab. JAMA Oncol. 2017;3(5):601-607. doi:10.1001/jamaoncol.2016.5745](https://jamanetwork.com/journals/jamaoncology/fullarticle/2648315)